Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
2012 ◽
Vol 65
(4)
◽
pp. 705-721
◽
2018 ◽
Vol 169
◽
pp. 265-272
◽
Keyword(s):
2018 ◽
Vol 107
◽
pp. 2320-2333
◽
2020 ◽
Vol 21
(1)
◽
pp. 99-106
◽
2019 ◽
Vol 26
(8)
◽
pp. 7772-7784
◽
Keyword(s):